Comments
Zydus Cadila has received the final approval from the USFDA to market exemestane tablets 25 mg. It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad. The estimated sale for exemestane tablets is $68.6 million. Exemestane is used in women after menopause for the treatment of early breast cancer. The group now has 220 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY04. Shares of Cadila Healthcare slipped 0.94 per cent at ₹379.10 on the BSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.